In the regulatory filing, Piramal Pharma said that observations are mainly related to procedural improvements and are not linked to data integrity. The company is preparing a detailed response and plans to submit it within the stipulated timeframe.
“Observations are most related to the improvement of action and transaction, and not with data integrity,” said Pirmal Pharma. The company is preparing a detailed response to the above observations, which will be submitted to the agency in a fixed deadline. The company confirmed its commitment to maintain high compliance standards and expressed confidence in addressing observations effectively.
Also read: List of Hexaware Technologies IPOs today. What GMP signs before debut?
Piramal Pharma Q3 Earnings
-
Stock Stock
Maximum return by investing in the right companies
-
Stock Stock
Ranko chart pattern made smooth
-
Stock Stock
Candles make easy: a course of candlestick patterns
-
Stock Stock
Dow theory smoothed
-
Stock Stock
Market 101: Trendlines and velocity insights
-
Stock Stock
Markets 102: Mastering Sentiment Indicators for Swing and Standing Trade
-
Stock Stock
Market 103: Mastering trends with RMI and Techno-Funda insights
-
Stock Stock
Market 104: Options Trading: Kickstart your F&O Adventure
-
Stock Stock
ROC Maid Easy: Master Course for ROC Stock Indicator
-
Stock Stock
RSI made easy: RSI Trading Course
-
Stock Stock
Technical analysis for each – a technical analysis course
-
Stock Stock
The introduction of technical analysis and candle principle
Piramal Pharma spent Rs 10 crore in the same quarter last year. A net profit of Rs 4 crore was registered. Revenue from operations has increased to 2,204 crore annually in Q3FY25. EBITD has increased by 6% to Rs. 350 crore, while EBITDA margin has dropped 100 basis points to 16%.
Also read: Stocks in News: Vedanta, RVNL, Max Healthcare Institute, Alcargo Gatey and Affordable Robotic
Pirmal Pharma Share Target Price
According to Trendlin data, the average target price of the stock is Rs 306, which indicates 55% from the current market price. The consensus recommendation of 7 analysts for stock is a ‘strong purchase’.
Piramal Pharma shares display
On Tuesday, Piramal Pharma’s shares closed down 1.1% on BSE, down 197.1%, while the benchmark Sensex fell 0.04%. In the last three months, the stock has dropped 22% but has increased 47% in the last 12 months. The company has a market capitalization of Rs 26,203 crore.
Also read: FII sales are likely to be less than April, the Nifty can touch 25,000 by December: Amk
(Connection: The recommendations, suggestions, opinions and opinions provided by experts are their own. This does not represent opinions of economic time)
(Now you can subscribe to our Etmarkets WhatsApp channel)
